Home / Stocks / HQY

Healthequity (HQY, Health insurers) Stock Valuation & Fair Value

Weak on forward returns

Healthequity (HQY, Health insurers) trades at a current P/E of 22.8, about 57% below its historical normal valuation, with a forward growth estimate of 11.5% and a PEG of 1.99. Analysts' one-year estimates have been hit 36% of the time. Priced at its historical normal P/E of 53.1 on the same blended earnings, the 2026-11-06 close of $103.63 corresponds to about $241 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

Current P/E
22.8
Normal P/E
53.1
PEG
1.99
Fwd growth
11.5%
Div yield
0.0%
RSI (14)
59.2
Neutral
Technical context
  • Price $103.63 at the Nov 6 close, 4.6% above the 20-day average ($99.03) and 8.5% above the 50-day ($95.52).
  • RSI (14) at 59.2.
  • 52-week range $73.21 to $108.84: the price is 4.8% below the high and 41.6% above the low.

The Street vs SeerForecast

Wall Street's mean price target for HQY is $120.67 across 15 analysts, 16.4% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: weak on forward returns. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from weak on forward returns (2026-08-21) to favorable on our tests (2026-11-02). New rating rules took effect in the week of 2026-11-02, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Current P/E and rating by weekCurrent P/E moved from 23.7 to 22.6 between 2026-08-21 and 2026-10-30, against a normal P/E of 53.1, with 1 rating change over 11 recorded weeks.2026-08-21: P/E 23.7, Weak on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 24.0, Weak on forward returns, recorded live 2026-08-242026-08-27: P/E 24.0, Weak on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 24.0, Weak on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 24.0, Weak on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 21.8, Weak on forward returns, recorded live 2026-08-312026-09-04: P/E 21.8, Weak on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 21.7, Weak on forward returns, recorded live 2026-09-072026-09-11: P/E 21.7, Weak on forward returns, recalculated for the week of 2026-09-122026-09-11: P/E 21.7, Weak on forward returns, recorded live 2026-09-142026-09-18: P/E 21.7, Weak on forward returns, recalculated for the week of 2026-09-192026-09-18: P/E 21.4, Weak on forward returns, recorded live 2026-09-212026-09-25: P/E 21.4, Weak on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 19.8, Weak on forward returns, recorded live 2026-09-282026-10-02: P/E 19.8, Weak on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 20.1, Weak on forward returns, recorded live 2026-10-052026-10-09: P/E 20.1, Weak on forward returns, recalculated for the week of 2026-10-102026-10-09: P/E 20.6, Weak on forward returns, recorded live 2026-10-122026-10-16: P/E 20.6, Weak on forward returns, recalculated for the week of 2026-10-172026-10-16: P/E 20.4, Weak on forward returns, recorded live 2026-10-192026-10-23: P/E 23.0, Weak on forward returns, recorded live 2026-10-262026-10-30: P/E 23.0, Favorable on our tests, recalculated for the week of 2026-10-312026-10-30: P/E 22.6, Favorable on our tests, recorded live 2026-11-0220.030.040.050.0Aug 21Sep 8Sep 25Oct 12Oct 30Normal P/E 53.1
Favorable on our testsWeak on forward returns

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-08-21P/E 23.7-55%Weak on forward returns (recalculated)
2026-08-24P/E 24.0-55%Weak on forward returns
2026-09-28P/E 19.8-63%Weak on forward returns
2026-10-31P/E 23.0-57%Favorable on our tests (recalculated) (across a rating rules change)
2026-11-02P/E 22.6-58%Favorable on our tests ← now
Show all 23 readings
WeekCurrent P/EPremium to normal P/ERating
2026-08-21P/E 23.7-55%Weak on forward returns (recalculated)
2026-08-24P/E 24.0-55%Weak on forward returns
2026-08-27P/E 24.0-55%Weak on forward returns (recalculated)
2026-08-28P/E 24.0-55%Weak on forward returns (recalculated)
2026-08-30P/E 24.0-55%Weak on forward returns (recalculated)
2026-08-31P/E 21.8-59%Weak on forward returns
2026-09-05P/E 21.8-59%Weak on forward returns (recalculated)
2026-09-07P/E 21.7-59%Weak on forward returns
2026-09-12P/E 21.7-59%Weak on forward returns (recalculated)
2026-09-14P/E 21.7-59%Weak on forward returns
2026-09-19P/E 21.7-59%Weak on forward returns (recalculated)
2026-09-21P/E 21.4-60%Weak on forward returns
2026-09-26P/E 21.4-60%Weak on forward returns (recalculated)
2026-09-28P/E 19.8-63%Weak on forward returns
2026-10-03P/E 19.8-63%Weak on forward returns (recalculated)
2026-10-05P/E 20.1-62%Weak on forward returns
2026-10-10P/E 20.1-62%Weak on forward returns (recalculated)
2026-10-12P/E 20.6-61%Weak on forward returns
2026-10-17P/E 20.6-61%Weak on forward returns (recalculated)
2026-10-19P/E 20.4-62%Weak on forward returns
2026-10-26P/E 23.0-57%Weak on forward returns
2026-10-31P/E 23.0-57%Favorable on our tests (recalculated) (across a rating rules change)
2026-11-02P/E 22.6-58%Favorable on our tests ← now

Frequently asked questions

Is Healthequity stock overvalued?

At a current P/E of 22.8 versus its historical normal P/E of 53.1, Healthequity trades about 57% below its typical valuation, with a PEG of 1.99 on 11.5% forward growth. tickerseer currently rates it weak on forward returns.

What is Healthequity's fair value and PEG?

Healthequity trades at a current P/E of 22.8 against a historical normal P/E of 53.1, a PEG of 1.99, and a forward growth estimate of 11.5%. Priced at its historical normal P/E of 53.1 on the same blended earnings, the 2026-11-06 close of $103.63 corresponds to about $241 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Healthequity changed?

tickerseer's rating moved from weak on forward returns (2026-08-21) to favorable on our tests (2026-11-02). New rating rules took effect in the week of 2026-11-02, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

What is the analyst price target for Healthequity?

The mean Wall Street price target for Healthequity is $120.67 across 15 analysts, 16.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health insurers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.